MICROBIAL DRUG RESISTANCEVolume 24, Number 5, 2018ªMary Ann Liebert, Inc.DOI: 10.1089/mdr.2017.0383
Antibiotic resistance (ABR) is a worldwide publichealth concern, with serious health, economic, and so-cietal repercussions. Its emergence is att...ributed to the se-lective pressure exerted by antibiotic use in the community, hospitals, veterinary health, agriculture, aquaculture, and the environment. Additionally aggravating the situation is the fact that very few new antibiotics have recently been produced by pharmaceutical companies. It is widely acknowledged that food animals are key reservoirs of antibiotic-resistant bacteria and that antibiotic usage in this population favors the emergence, selection, and spread of resistance among animals and humans, both through zoonoses (infectious diseases trans-mitted between animals and humans) and the food chain.
more
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant
tuberculosis (XDR-TB) increasingly occur in resource-constrained settings.
In the context of a national response to MDR- and XDR-TB, health workers in
TB clinics (in distric...t hospitals and some accredited health centres) will need
to diagnose MDR-TB, initiate second-line anti-TB drugs, and monitor MDRTB
treatment.
Management of MDR-TB: a field guide was created to help health workers
carry out these tasks. It is a job aid that medical officers and TB nurses
are meant use frequently during the day for quick reference. This module
is closely related to other clinical guideline modules in the Integrated
Management of Adolescent and Adult Illness (IMAI) series. In particular, the
approach to chronic disease management is taken from General principles
of good chronic care in the IMAI series.
more
Guidelines for Therapy and Management of Urinary Tract Infection
Guidelines for Management and Therapy of Atrial Fibrillation in Indonesia
Guidelines for Therapy and Management of Acute Coronary Syndrome in Indonesia
Therapeutic Guidelines for Using Implant Cardiovascular Electronic Device in Indonesia
Guidelines for treatment of drug-susceptible tuberculosis and patient care
2017 update
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Update 2017
6th edition, The NLEM 2021 contains 398 drugs molecules in different therapeutic categories.
The Panel recommendations on initial combination regimens for the antiretroviral therapy (ART)-naive, HIV-infected patients.
Practical Guidelines of Insulin Therapy in Diabetes Mellitus Patients
Guidelines for the Management and Therapy of Urinary Tract Infection and Male Genitalia in Indonesia
Guidelines for treatment of drug-susceptible tuberculosisand patient care
2017 Update
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Uptsate 2017
Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug treatment be continued after remission in order to allow for the best outcomes?
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the dru...g development process towards important regimen characteristics corresponding to the needs of end-users.
more
The resources provide both the older as well as the updated Operational Guidelines for antiretroviral therapy centres, including administrative issues, functions and establishment of centres, reporting and recording tools, measures to improve retent...ion in HIV care, supply chain management of drugs and various other aspects that are essential to ensure quality treatment for people living with HIV/AIDS.
more
The use of Delamanid and Bedaquiline for Children with Drug-Resistant Tuberculosis.
This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blocke...rs and Janus kinase (JAK) inhibitors in patients with severe or critical COVID-19, and modifies previous recommendations for the neutralizing monoclonal antibodies sotrovimab and casirivimab-imdevimab in patients with non-severe COVID-19.
more
19 February 2021
The overall objective of this prospective meta-analyses (PMA) is to estimate the effect of anti-IL-6 therapy compared with usual care in hospitalized patients with suspected or confirmed COVID-19. The primary comparison is of the c...lass effect of anti-IL-6 therapies. It will also estimate the effects of specific anti-IL-6 therapies.
more